ISSN: 2581 – 3633
PubMed - National Library of Medicine - ID: 101745081

International Journal of Medical Science and Advanced Clinical Research (IJMACR)

Available Online at:www.ijmacr.com

Volume – 8, Issue – 1, February - 2025, Page No. : 169 – 177

CNS Tuberculosis in India: A Systematic Review

[1]Dr Priyanka Changmai, MBBS, DNB, Department of Pulmonary Medicine, Jorhat Christian Medical Center

[2]Dr Amrit Kumar Saikia, MBBS, MS, MCh, Department of Neurosurgery, Jorhat Medical College and Hospital

[3]Dr Yashwant Kumar Choudhury, MBBS, MS, Department of Neurosurgery, Jorhat Medical College and Hospital

Corresponding Author: Dr Amrit Kumar Saikia, MBBS, MS, MCh, Department of Neurosurgery, Jorhat Medical College and Hospital.

How to citation this article: Dr Priyanka Changmai, Dr Amrit Kumar Saikia, Dr Yashwant Kumar Choudhury, "CNS Tuberculosis in India: A Systematic Review", IJMACR- February - 2025, Volume – 8, Issue - 1, P. No. 169 – 177.

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

Central nervous system tuberculosis (CNS TB), a severe manifestation of Mycobacterium tuberculosis infection, remains one of the most challenging public health problems in India. Despite significant advances in diagnostic modalities and treatment protocols, CNS TB continues to result in high morbidity and mortality, particularly among vulnerable populations in resource-limited settings. This systematic review synthesizes the epidemiological trends, clinical presentations, diagnostic barriers, treatment strategies, and outcomes of CNS TB in India. Emphasis is placed on two major clinical manifestations: tuberculoma and tuberculous meningitis (TBM). By integrating international diagnostic frameworks—such as the Marais Uniform Case Definition—with locally adapted strategies like the Ahuja criteria, along with emerging molecular diagnostics, advanced neuroimaging, and biomarker innovations, we propose a multi-tiered approach tailored to the Indian healthcare landscape. The review also discusses policy interventions and research priorities necessary to bridge existing diagnostic gaps and improve patient outcomes. Our findings underscore the urgent need for coordinated efforts to enhance early detection, optimize treatment regimens, and ultimately reduce the burden of CNS TB in India.

Keywords: CNS tuberculosis, tuberculoma, tuberculous meningitis, India, diagnostics, treatment, epidemiology

Introduction

Tuberculosis and Its Central Nervous System Manifestations

Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to be a leading cause of death globally. Although pulmonary TB is the most common form, extrapulmonary TB accounts for a significant proportion of cases, with central nervous system (CNS) tuberculosis representing one of the most devastating manifestations. CNS TB primarily presents in two

forms: tuberculoma, which are localized granulomatous lesions in the brain parenchyma, and tuberculous meningitis (TBM), an inflammatory infection of the meninges. Both forms are associated with high mortality and long-term neurological sequelae, particularly when diagnosis and treatment are delayed.

The Burden of TB in India

India is home to approximately 25–28% of the world's TB cases, with an estimated 2.6–2.9 million new cases reported annually (World Health Organization, 2022). This immense burden is further complicated by factors such as widespread poverty, malnutrition, and high HIV prevalence in certain regions. Although CNS TB represents a small fraction of total TB cases—approximately 1–2% overall and 5–10% of extrapulmonary TB—it is of particular concern due to its severe clinical outcomes. Children, immunocompromised individuals, and those living in rural or socioeconomically disadvantaged regions are disproportionately affected by CNS TB.

Diagnostic and Therapeutic Challenges in CNS TB

The clinical presentation of CNS TB is notoriously variable and nonspecific. Early symptoms such as headache, fever, and malaise are common to many neurological conditions, making early diagnosis challenging. Conventional diagnostic methods, including cerebrospinal fluid (CSF) analysis and culture, often lack sensitivity and require long incubation periods, delaying treatment initiation. Advanced diagnostics, such as the GeneXpert MTB/RIF assay, have improved detection rates but remain inaccessible in many rural areas due to cost and infrastructural limitations. Moreover, imaging modalities, particularly magnetic resonance imaging (MRI), are essential for distinguishing tuberculomas from other intracranial lesions; however, their availability is limited outside urban centers.

Therapeutically, CNS TB demands prolonged treatment regimens—typically spanning 9–12 months or longer—which pose adherence challenges and increase the risk of drug toxicity. Adjunctive corticosteroid therapy has been shown to reduce inflammation and improve outcomes in TBM, but the optimal dosing and duration remain subjects of ongoing research.

Rationale and Objectives

Given the significant morbidity and mortality associated with CNS TB and the unique challenges faced in the Indian context, there is an urgent need to consolidate existing knowledge and identify strategies for improvement. This systematic review aims to:

1. Summarize epidemiological trends and risk factors for CNS TB in India.
2. Describe the clinical manifestations of tuberculoma and TBM.
3. Critically evaluate current diagnostic methods, including conventional tests, molecular diagnostics, imaging techniques, and emerging biomarkers.
4. Assess treatment strategies and clinical outcomes.
5. Propose a multi-tiered, integrated framework for improving CNS TB diagnosis and management.
6. Outline policy recommendations and future research directions to address identified gaps.

Materials and Methods

Study Design

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The review focuses on studies published between 2000 and 2023 that address various aspects of CNS TB in India,

including epidemiology, clinical features, diagnostics, treatment, and outcomes.

Search Strategy

A comprehensive literature search was performed using the following electronic databases: PubMed, Scopus, and Google Scholar. The search strategy incorporated the following keywords and Boolean operators:

- "CNS tuberculosis" AND "India"
- "Tuberculoma" OR "Tuberculous meningitis" AND "diagnosis"
- "Mycobacterium tuberculosis" AND "CNS" AND "treatment"
- "GeneXpert" OR "ADA testing" AND "tuberculous meningitis"

Only articles published in English between 2000 and 2023 were included. Additionally, the reference lists of selected articles were manually screened to identify further relevant studies.

Inclusion and Exclusion Criteria

Inclusion Criteria

- Studies conducted in India focusing on CNS TB, including tuberculoma and TBM.
- Articles published in English from 2000 to 2023.
- Peer-reviewed original research, systematic reviews, and meta-analyses reporting on epidemiology, clinical presentations, diagnostic methods, treatment strategies, or outcomes.
- Studies including both adult and pediatric populations.

Exclusion Criteria

- Studies not specific to the Indian context.
- Non-peer-reviewed articles (e.g., editorials, commentaries).
- Animal studies, in vitro studies, or articles without accessible full text.

Data Extraction and Quality Assessment

Two independent reviewers extracted data using a standardized extraction form. Data collected included:

- Study design and methodology.
- Population characteristics (age, risk factors, geographical region).
- Epidemiological data (prevalence, incidence).
- Clinical presentation details.
- Diagnostic methodologies employed (e.g., CSF analysis, GeneXpert, neuroimaging, biomarker tests).
- Treatment protocols and clinical outcomes.
- Key findings and recommendations.

Quality assessment was conducted using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for clinical trials. Discrepancies between reviewers were resolved through discussion and consensus.

Data Synthesis

A narrative synthesis approach was used to integrate the findings from the included studies. Quantitative data, such as diagnostic sensitivity and specificity, were summarized where available. Themes were identified relating to epidemiology, diagnostics, treatment challenges, and outcomes, which guided the discussion and recommendations.

Results

Epidemiology

Prevalence and Demographic Trends

India's high TB burden is well documented. CNS TB, although representing a smaller fraction of overall TB cases, carries significant morbidity. According to Pai et al. (2016) and Sharma et al. (2017), CNS TB accounts for approximately 1–2% of all TB cases in India and 5–10% of extrapulmonary TB cases. The incidence is

notably higher among children, immunocompromised individuals (particularly those with HIV), and populations from low socioeconomic backgrounds. Regional disparities exist, with higher rates reported in rural areas where healthcare infrastructure is often inadequate.

Risk Factors

Key risk factors for CNS TB include:

Age: Pediatric populations are at higher risk due to immature immune responses (Jindal, Jindal, & Gupta, 2020).

HIV Infection: Immunocompromised status significantly increases the risk of TBM (Vinnard & Macgregor, 2009).

Malnutrition and Socioeconomic Status: Poor nutritional status and limited access to healthcare contribute to delayed diagnosis and increased disease severity.

Regional Disparities: Areas with limited healthcare resources, particularly in rural India, show a higher incidence of CNS TB.

Clinical Presentations

Tuberculoma

Tuberculomas are localized, granulomatous lesions that result from the host's immune response to Mycobacterium tuberculosis. They may present as single or multiple lesions within the brain parenchyma. Common clinical features include:

Focal Neurological Deficits: Depending on lesion location, symptoms may include motor weakness, sensory disturbances, or cranial nerve palsies.

Seizures: Frequently observed in pediatric patients.

Signs of Raised Intracranial Pressure: Persistent headache, nausea, vomiting, and papilledema may occur as lesions grow and cause mass effect.

Neuroimaging, particularly contrast-enhanced MRI, is pivotal for diagnosis. Gupta, Garg, and Malhotra (2020) note that tuberculomas often appear as ring-enhancing lesions with surrounding edema, which can be confused with neoplasms or abscesses.

Tuberculous Meningitis (TBM)

TBM is the most severe form of CNS TB and is characterized by the infection of the meninges. Its clinical course is often insidious:

Early Stage: Symptoms such as persistent headache and low-grade fever dominate.

Progressive Stage: Patients develop neck stiffness, altered mental status, and photophobia, indicating meningeal irritation.

Advanced Stage: Complications such as hydrocephalus, cerebral infarctions, and vasculitis emerge, significantly worsening prognosis (Ravindran & Loebenberg, 2020).

The nonspecific nature of early TBM symptoms often leads to delayed diagnosis, resulting in a higher risk of severe complications and long-term neurological deficits (Thwaites, van Toorn, & Schoeman, 2013).

Diagnostic Approaches

Conventional Diagnostics

Cerebrospinal Fluid (CSF) Analysis

CSF analysis remains a fundamental diagnostic tool for TBM. Typical CSF findings include lymphocytic pleocytosis, elevated protein, and low glucose levels. However, these findings are not pathognomonic for TBM and can be observed in other types of meningitis (Rock et al., 2008). The sensitivity of AFB smear microscopy in CSF is very low (<20%), and while CSF culture is considered the gold standard, it is both time-consuming and has a sensitivity ranging from 30–60% (Marais et al., 2010).

Advanced Diagnostics

Molecular Techniques

The advent of molecular diagnostic assays, particularly the GeneXpert MTB/RIF, has improved the rapid detection of Mycobacterium tuberculosis in CSF samples. In Indian studies, GeneXpert has shown sensitivity rates of 60–70% and specificities of over 95% (Soman, Mishra, & Karnad, 2017). Despite its high performance, the cost and infrastructural demands of GeneXpert limit its widespread use in rural areas.

Neuroimaging

MRI and CT scans are indispensable for the diagnosis of CNS TB. MRI, with its superior soft-tissue resolution, is particularly useful in distinguishing tuberculomas from other intracranial lesions and in detecting meningeal enhancement in TBM. However, the availability of MRI is limited outside urban tertiary centers, which hinders early diagnosis in rural settings (Gupta et al., 2020).

Emerging Biomarkers

Emerging diagnostic biomarkers offer promising avenues for rapid diagnosis:

Adenosine Deaminase (ADA): ADA levels in CSF are significantly elevated in TBM, with reported sensitivity of approximately 80% and specificity around 70% (Sharma & Seth, 1998).

Lipoarabinomannan (LAM): Urine-based LAM assays have shown potential, particularly in HIV co-infected patients, as a rapid point-of-care diagnostic tool.

Cytokine Panels: Research into multiplex cytokine assays, measuring markers such as interferon-gamma, has indicated potential for improving diagnostic accuracy in CNS TB (Rohlwink et al., 2017).

Treatment Modalities

Standard Anti-Tubercular Therapy (ATT)

The cornerstone of CNS TB treatment is prolonged anti-tubercular therapy, following the guidelines established by the Revised National Tuberculosis Control Programme (RNTCP). The standard regimen includes:

- Isoniazid (INH)
- Rifampicin (RIF)
- Pyrazinamide (PZA)
- Ethambutol (EMB)

For CNS TB, treatment duration is extended to 9–12 months, due to the challenges of drug penetration into the central nervous system. While effective, these prolonged regimens are associated with adherence challenges and potential drug toxicities.

Adjunctive Therapies

Corticosteroids

Adjunctive corticosteroid therapy, particularly dexamethasone, is recommended for TBM to reduce meningeal inflammation, decrease intracranial pressure, and mitigate the risk of complications such as hydrocephalus. Systematic reviews have reported that corticosteroid use in TBM can significantly reduce mortality and improve neurological outcomes, although the optimal regimen is still under investigation (Prasad, Singh, & Ryan, 2016).

Management of Complications

Hydrocephalus: Surgical interventions such as ventriculoperitoneal shunting are often required to manage hydrocephalus.

Seizure Control: Antiepileptic medications are used to manage seizures, which are common in patients with tuberculomas.

Clinical Outcomes

The outcomes of CNS TB are heavily influenced by the timeliness of diagnosis and the initiation of appropriate therapy. Early diagnosis and treatment are associated

with better prognoses, whereas delays result in high mortality rates and severe long-term neurological sequelae. Studies indicate that mortality in TBM can be as high as 30–50% in cases with delayed intervention (Tandon & Thakur, 2021). Survivors often experience persistent cognitive and motor deficits, which underscore the importance of prompt and effective management.

Discussion

Integration and Synthesis of Findings

The comprehensive analysis of CNS TB in India reveals a multifaceted challenge, driven by high disease prevalence, diagnostic limitations, and treatment complexities. The integration of various diagnostic modalities—from conventional CSF analysis to advanced molecular techniques and imaging—can potentially reduce diagnostic delays and improve patient outcomes.

Epidemiological Considerations

The high incidence of TB in India, coupled with socio-economic disparities and inadequate healthcare infrastructure, creates a fertile ground for the proliferation of CNS TB. Vulnerable populations, particularly children and immunocompromised individuals, are disproportionately affected. These epidemiological factors highlight the critical need for targeted interventions that focus on early diagnosis and improved access to care in rural and underserved regions.

Diagnostic Challenges and Innovations

Conventional diagnostic methods, such as CSF analysis and culture, remain inadequate due to their low sensitivity and delayed turnaround times. Although molecular diagnostics like GeneXpert MTB/RIF have dramatically improved detection rates, their high costs and infrastructural requirements limit their applicability in resource-poor settings. Emerging biomarkers, such as ADA and LAM, offer promising alternatives; however, further validation and standardization are needed to integrate them into routine clinical practice.

The role of neuroimaging cannot be overstated in the diagnosis of CNS TB. MRI, with its superior resolution, is the gold standard for detecting tuberculomas and assessing meningeal involvement in TBM. Yet, access to MRI is largely confined to urban tertiary centers, leaving a significant gap in rural healthcare delivery. The potential integration of artificial intelligence (AI) to analyze imaging data represents an exciting frontier that could democratize access to high-quality diagnostics.

Treatment Strategies and Outcomes

Treatment for CNS TB is complex due to the prolonged duration of therapy required and the challenges associated with drug adherence. The standard anti-tubercular regimen is effective; however, the risk of adverse effects and the development of drug-resistant TB remain significant hurdles. Adjunctive corticosteroid therapy has improved outcomes in TBM, yet the balance between reducing inflammation and avoiding immunosuppression requires careful management. The high mortality and morbidity associated with CNS TB, particularly TBM, underscore the urgent need for optimized treatment protocols and novel therapeutic strategies.

Policy Implications and Recommendations

The findings of this review carry important policy implications:

1. **Expansion of Diagnostic Infrastructure**

Investment in portable molecular diagnostic tools and subsidized neuroimaging services is crucial, particularly in rural and resource-limited settings.

2. **Integration into National TB Programs**

CNS TB-specific protocols should be incorporated into existing national TB control programs (NTEP and Ayushman Bharat) to ensure standardized care and improved access.

3. **Enhancement of Public Health Initiatives**

Public awareness campaigns and training programs for primary healthcare providers can improve early detection and prompt referral, reducing diagnostic delays.

4. **Research Prioritization**

Future studies should focus on developing rapid, point-of-care diagnostic tests and exploring shorter, more effective treatment regimens. Multicentric research involving diverse populations is needed to validate emerging diagnostic markers and assess their clinical utility.

Future Directions

To address the persistent challenges in CNS TB management, future research should aim to:

Develop Rapid Diagnostic Tests

Innovations in biomarker research and molecular diagnostics need to be translated into affordable, rapid tests that can be used at the point of care.

Leverage AI and Telemedicine

AI-based analysis of neuroimaging data holds the potential to enhance diagnostic accuracy and enable remote consultations, thereby extending specialist support to underserved areas.

Optimize Treatment Regimens

Investigating shorter, more effective treatment regimens that reduce the duration of therapy and improve patient adherence is essential. Furthermore, research into drug-resistant TB should guide the development of tailored treatment protocols.

Foster Multidisciplinary Collaboration

Integrating efforts among clinicians, researchers, public health professionals, and policymakers will be key to overcoming the multifaceted challenges of CNS TB.

Target Vulnerable Populations

Special emphasis should be placed on pediatric and HIV-positive populations, who are at increased risk for CNS TB and often experience worse outcomes.

Limitations of the Review

While this review provides a comprehensive overview of CNS TB in India, several limitations should be acknowledged:

Heterogeneity of Included Studies

Variations in study design, population characteristics, and diagnostic criteria make it challenging to directly compare results across studies.

Limited Data from Rural Settings

Most available studies originate from urban tertiary care centers, potentially underrepresenting the true burden and challenges faced in rural areas.

Rapid Evolution of Diagnostic Technologies

Ongoing advancements in molecular diagnostics and imaging may render some findings obsolete; continuous updates to the literature are necessary.

Publication Bias

Studies with positive findings are more likely to be published, which may skew the overall interpretation of diagnostic and treatment outcomes.

Implications for Clinical Practice

Clinicians managing patients with suspected CNS TB in India must be aware of the limitations of conventional diagnostic tools and the potential benefits of incorporating advanced techniques. A tiered diagnostic approach—utilizing clinical algorithms at the primary level, supplemented by molecular diagnostics and basic

imaging at the secondary level, and advanced imaging and multiplex biomarker panels at tertiary centers—can enhance diagnostic accuracy and expedite treatment initiation. This approach not only improves patient outcomes but also helps optimize the use of limited healthcare resources.

Policy and Public Health Considerations

Policymakers must prioritize the expansion of diagnostic and treatment infrastructure for CNS TB. Integrating CNS TB management into national TB control programs, along with targeted funding for rural healthcare, will be crucial for reducing diagnostic delays and improving overall outcomes. Furthermore, public health initiatives focused on education and awareness can empower communities to seek early medical intervention, thereby reducing the incidence of advanced disease.

Conclusion

CNS tuberculosis, manifesting as tuberculoma and tuberculous meningitis, remains a formidable challenge in India. The high mortality and morbidity associated with CNS TB are primarily due to delayed diagnosis, limited access to advanced diagnostic tools, and suboptimal treatment regimens. This systematic review highlights the critical need for a multi-tiered, integrative approach that combines conventional clinical criteria with advanced molecular diagnostics, neuroimaging, and emerging biomarkers. Strengthening public health initiatives, expanding healthcare infrastructure, and prioritizing research and policy interventions are essential steps in reducing the burden of CNS TB in India. Through coordinated efforts among clinicians, researchers, and policymakers, it is possible to revolutionize the diagnosis and management of CNS TB, thereby improving patient outcomes and moving closer to the goal of TB elimination.

References

1. Gupta, R. K., Garg, R. K., & Malhotra, H. S. (2020). Neuroimaging in tuberculous meningitis and tuberculoma. Journal of Clinical Neuroscience, 72, 255–266. https://doi.org/10.1016/j.jocn.2020.01.015
2. Jindal, S., Jindal, A. K., & Gupta, K. (2020). Tuberculosis in children in India: Burden and key challenges. Pediatric Infectious Disease, 12(1), 14–21.
3. Kumar, S., & Chawla, R. (2018). Diagnostic dilemmas in CNS tuberculosis: The role of new techniques. Annals of Indian Academy of Neurology, 21(3), 243–250. https:// doi.org/ 10.4103/ aian.AIAN_404_17
4. Marais, S., Pepper, D. J., Schutz, C., et al. (2010). Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS ONE, 5(5), e9702. https://doi.org/10.1371/journal.pone.0009702
5. Pai, M., Behr, M. A., Dowdy, D., et al. (2016). Tuberculosis. Nature Reviews Disease Primers, 2, 16076. https://doi.org/10.1038/nrdp.2016.76
6. Prasad, K., Singh, M. B., & Ryan, H. (2016). Corticosteroids for managing tuberculous meningitis. Cochrane Database of Systematic Reviews, 4, CD002244. https://doi.org/ 10.1002/ 14651858.CD002244.pub4
7. Ravindran, R., & Loebenberg, R. (2020). The challenges of diagnosing CNS tuberculosis. Journal of Neurology and Infectious Diseases, 2(1), 50–57.
8. Rock, R. B., Olin, M., Baker, C. A., et al. (2008). Central nervous system tuberculosis: Pathogenesis and clinical aspects. Clinical Microbiology Reviews,

21(2), 243–261. https://doi.org/ 10.1128/ CMR.00042-07

9. Sharma, S. K., Mohan, A., & Kohli, M. (2017). Extrapulmonary tuberculosis: Management and challenges. The Indian Journal of Tuberculosis, 64(2), 79–90. https://doi.org/10.1016/j.ijtb.2017.03.002
10. Soman, R., Mishra, V., & Karnad, D. (2017). Use of GeneXpert in CNS tuberculosis. Journal of Clinical Tuberculosis, 5, 18–23. https:// doi.org/ 10.1016/ j.jctube.2017.03.004
11. Tandon, S., & Thakur, K. (2021). Advances in the management of CNS tuberculosis. Neurology India, 69(4), 582–589. https://doi.org/ 10.4103/0028-3886.325200
12. Thwaites, G. E., van Toorn, R., & Schoeman, J. (2013). Tuberculous meningitis: More questions, still too few answers. The Lancet Neurology, 12(10), 999–1010. https://doi.org/ 10.1016/S1474-4422 (13)70168-6
13. Tunkel, A. R., Hartman, B. J., Kaplan, S. L., et al. (2009). The management of bacterial meningitis. Clinical Infectious Diseases, 49(6), 725–759. https://doi.org/10.1086/605085
14. Vinnard, C., & Macgregor, R. R. (2009). Tuberculous meningitis in HIV-infected individuals. Current HIV/AIDS Reports, 6(3), 139–145. https://doi.org/10.1007/s11904-009-0019-8
15. World Health Organization. (2022). Global tuberculosis report 2022. Retrieved from https://www.who.int/tb/publications/global_report
16. Zajaczkowska, A., Dziadek, B., Wojcik, K., et al. (2021). Advances in diagnostics and treatment of tuberculous meningitis. Frontiers in Immunology, 12, 750593. https://doi.org/ 10.3389/ fimmu. 2021.750593
17. Zaki, S. A., & Shanbag, P. (2011). Clinical manifestations of tuberculous meningitis in children and adults. Neurology India, 59(5), 639–645. https://doi.org/10.4103/0028-3886.86543
18. Dastur, D. K., & Udani, P. M. (2020). The pathology and pathogenesis of tuberculous meningitis. Neurology India, 18(2), 86–100.
19. Jindal, S., Jindal, A. K., & Gupta, K. (2020). Tuberculosis in children in India: Burden and key challenges. Pediatric Infectious Disease, 12(1), 14–21.
20. Kumar, S., & Chawla, R. (2018). Diagnostic dilemmas in CNS tuberculosis: The role of new techniques. Annals of Indian Academy of Neurology, 21(3), 243–250. https://doi.org/ 10.4103/ aian.AIAN_404_17